Co-Designing a Consumer-Focused Digital Reporting Health Platform to Improve Adverse Medicine Event Reporting:...

Area of Science:

• Digital health interventions
• Patient safety
• Pharmacovigilance

Background:

• Adverse medicine events (AMEs) are often underreported, with up to 70% going undetected by healthcare professionals.
• Low reporting rates to regulatory authorities hinder effective medicine safety monitoring.
• Increased reporting from consumers, healthcare professionals, and pharmaceutical companies is crucial for improving medicine safety.

Purpose of the Study:

• To co-design a digital reporting platform aimed at enhancing the detection and management of AMEs.
• To improve the reporting of AMEs to regulatory bodies by involving consumers and healthcare professionals.
• To leverage technology and user-centered design to address AME underreporting.

Main Methods:

• A 3-phase co-design methodology prioritizing stakeholder equity, guided by the Consolidated Framework for Implementation Research.
• Phase 1: Stakeholder engagement (consumers, healthcare professionals, regulators) through interviews, focus groups, and workshops to define platform standards.
• Phase 2: Prototyping, testing, and development of the digital platform with software developers and user interaction experts.
• Phase 3: Implementation and trial in South Australia, recruiting consumers to report AMEs, with process and outcome evaluations.

Main Results:

• Phase 1 will yield persona profiles and user journey maps to guide platform development.
• Phase 2 will focus on developing and refining a user-friendly platform and data visualization tool.
• Phase 3 will provide insights into the platform's impact on AME detection, management, and reporting.

Conclusions:

• A co-design approach is utilized to develop a digital platform for AME reporting, integrating stakeholder perspectives.
• The project aims to overcome AME underdetection and underreporting challenges by utilizing consumer and technological potential.
• The platform has the potential to improve individual patient safety and generate valuable data for regulatory medicine safety assessments.